JFK Neuroscience is a leader in Brain Tumor Research and Treatment

Since its inception in 1992, as an integral component of the JFK Neuroscience Institute, the Brain and Spine Tumor Institute at JFK Medical Center remains on the forefront of brain tumor treatment having participated in the most advanced immunotherapy trials and leading edge brain tumor research. As 1 of the 8 original sites that participated in the Tocagen Tg 511 11-01 trial and through several published articles, we have a better understanding of using immunotherapy in the treatment of malignant gliomas.

Bringing the highest level of surgical and medical skill together with advancements in technology, JFK was the first center in the United States certified to use the wearable, portable and innovative Optune device in treating glioblastoma (GBM). Led by Dr. Joseph Landolfi, the Director of Neuro-oncology and Radiosurgery, the Institute at JFK continues to lead national clinical trials in neuro oncology including:

• A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination with Cemiplimab-rwlc (Libtayo®) in Subjects with Recurrent or Progressive Glioblastoma. Ziopharm.
• STELLAR Study – A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy. Orbus Therapeutics.

Dr. Landolfi has authored a number of journal publications and book chapters and had multiple abstracts presented at national and international meetings. He is a recipient of the Gary Lichtenstein Humanitarian Award by the nationally recognized Voices Against Brain Cancer organization.

The Brain and Spine Tumor Institute at JFK Medical Center is one of the most comprehensive program for the diagnosis, management and recovery of brain and spinal cord tumor patients within a single hospital setting in the North East.